Introduction: Chronic kidney disease (CKD) in canines is a progressive condition characterized by a gradual decline in kidney function. There are significant gaps in understanding how CKD is managed in canines and the full extent of its impact. This study aimed to characterize disease management of CKD and its impact on dogs, their owners and the veterinary healthcare system in the United States of America (United States).
Methods: Data were drawn from the Adelphi Real World Canine CKD Disease Specific Programme™, a cross-sectional survey of veterinarians, pet owners and their dogs with CKD in the United States from December 2022 to January 2024. Veterinarians reported demographic, diagnostic, treatment, and healthcare utilization data, for dogs with CKD. Owners voluntarily completed questionnaires, providing data about their dog, as well as quality of life and work-related burden using the Dog Owners Quality of Life, and the Work Productivity and Activity Impairment questionnaires. Analyses were descriptive and Cohen's Kappa was used to measure agreement between owners and veterinarians.
Results: A total of 117 veterinarians provided data for 308 dogs, of which 68 owners also reported information. Discrepancies in recognizing symptoms of CKD in dogs, particularly excessive water consumption and urination, were identified between veterinary professionals and owners. Interventions for managing CKD in dogs focused on controlling symptoms and supporting kidney function through dietary modifications and medication. Owners of dogs with CKD reported minimal impact to overall work and activity impairment (10 and 14%, respectively). At diagnosis, 78.6% of dogs were International Renal Interest Society Stage I-II, and 21.5% were Stage III-IV. Regardless of CKD stage, owners strongly agreed that ownership provided them with emotional support and companionship. Regarding veterinary healthcare utilization, 95% of dogs were seen in general veterinary practices.
Discussion: These findings emphasize the value of real-world evidence in enhancing our understanding of CKD in companion animals and informs future strategy for the real-world diagnosis and treatment of CKD. The results also provide insights to the potential burden experienced by owners of dogs with CKD.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11886590 | PMC |
http://dx.doi.org/10.3389/fvets.2025.1502933 | DOI Listing |
Front Vet Sci
February 2025
Adelphi Real World, Bollington, United Kingdom.
Introduction: Chronic kidney disease (CKD) in canines is a progressive condition characterized by a gradual decline in kidney function. There are significant gaps in understanding how CKD is managed in canines and the full extent of its impact. This study aimed to characterize disease management of CKD and its impact on dogs, their owners and the veterinary healthcare system in the United States of America (United States).
View Article and Find Full Text PDFJ Vet Dent
March 2025
Karmiel Veterinary Center (KVC), Karmiel, Israel.
This report presents 2 cases of renal osteodystrophy in young to middle-aged dogs, emphasizing the clinical presentation, diagnostic challenges, and therapeutic management. Both cases exhibited similar symptoms including oral abnormalities and renal dysfunction, with radiographic evidence revealing substantial bone resorption in the mandibles and maxillae. Histological analysis post-mortem confirmed advanced chronic kidney disease characterized by extensive fibrosis and glomerular abnormalities.
View Article and Find Full Text PDFJ Vet Intern Med
February 2025
Small Animal Department, Ghent University, Merelbeke, Belgium.
Background: Neutrophil gelatinase-associated lipocalin (NGAL) and tissue inhibitor of metalloproteinase-2 (TIMP-2) have potential as early biomarkers for acute kidney injury (AKI) in dogs.
Objectives: Assess whether NGAL and TIMP-2 at admission (T0) and 24 h later (T1) identify survival in critically ill (CI) and AKI dogs, development of hospital-acquired AKI in CI dogs, and development of chronic kidney disease (CKD) in AKI dogs after 3 months.
Animals: Sixty-two client-owned dogs: 10 healthy, 24 with AKI, and 28 CI.
Vet Sci
February 2025
Department of Veterinary Medicine and Animal Sciences, University of Milan, Via dell'Università 6, 26900 Lodi, Italy.
Information about parathyroid hormone (PTH) status in the course of AKI is lacking. In contrast, renal secondary hyperparathyroidism (RSHPT) is a well-known consequence of canine chronic kidney disease (CKD). This study aimed to investigate PTH status in dogs affected by AKI, comparing PTH concentrations between healthy dogs, dogs affected by AKI and dogs affected by CKD.
View Article and Find Full Text PDFVet Pathol
February 2025
Small Animal Department, Faculty of Veterinary Medicine, Ghent University, Merelbeke, Belgium.
Liver-type fatty acid-binding protein (L-FABP) is expressed by several tissues, plays a role in fatty acid metabolism, and has antioxidant effects. Its renal expression is upregulated by stress. Urinary L-FABP (uL-FABP) is a promising kidney biomarker in people for detection of early acute and chronic kidney disease (CKD) and as a marker for progression in patients with glomerulonephritis.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!